EU/3/19/2200

About

On 21 August 2019, orphan designation EU/3/19/2200 was granted by the European Commission to Dr Sebastian Canisius, Germany, for clofazimine for the treatment of nontuberculous mycobacterial lung disease.

The sponsorship was transferred to Aclira Consulting GmbH, Germany in January 2021.

Key facts

Active substance
Clofazimine
Disease / condition
Treatment of nontuberculous mycobacterial lung disease
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2200

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Aclira Consulting GmbH
Hohmannsweg 8 
Heskem
35085 Ebsdorfergrund 
Hassia 
Germany 
Email: info@aclira.de

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating